Table 3

Infectious complications in common variable immunodeficiency

Mount Sinai 1999 [3](n = 248)

Mount Sinai 2011 [38](n = 473)

DEFI 2008 [4](n = 252)


Recurrent (respiratory tract) infections

98% (243/248)

94% (445/473)

91% (230/252)

Pneumoniaa

76.6% (190/248)

40% (187/473)

58% (147/252)

Meningitis

<1% (2/248)

NS

7.9% (20/252)

Viral hepatitis

6.5% (16/248)

3.4% (16/473)

1.2% (3/252)

Giardia enteritis

3.2% (8/248)

2.3% (11/473)

13.9% (35/252)

(Recurrent) Herpes zoster

3.6% (9/248)

2.5% (12/473)

11% (27/252)

Pneumocystis jiroveci infection

2.8% (7/248)

1.3% (6/473)

<1% (2/252)

Salmonella infection

1.2% (3/248)

<1% (4/473)

7.5% (19/252)

Mycoplasma infection

2.8% (7/248)

<1% (4/473)

NS

Candidiasis

1.2% (3/248)

<1% (3/473)

<1% (2/252)

Mycobacterial disease

<1% (1/248)

<1% (3/473)

<1% (2/252)

Papilloma viral infection

NS

<1% (3/473)

<1% (13/252)


aPredominantly bacterial, lobar or bronchopneumonia, X-ray proven. NS, not specified.

Salzer et al. Arthritis Research & Therapy 2012 14:223   doi:10.1186/ar4032